Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

Radiotherapy-Induced Skin Fibrosis: Pathophysiology, Emerging Therapeutics, and the Role of Dermatology.

Burke OM., Bilik SM., Dodson C., Johnson J., Ferrari L., Imisheva K.

Narrative Review on Hip, Systemic / IV, published in Am J Clin Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Am J Clin Dermatol (2026)
Country
New Zealand
Reported sample size
—
Source database
PubMed
PMID
41729414
PMCID
PMC13033031
DOI
10.1007/s40257-026-01007-4

Abstract (original English)

Radiotherapy-induced skin fibrosis is a chronic progressive complication of radiotherapy that impairs function, aesthetics, and quality of life yet remains under-recognized and undertreated. While acute cutaneous toxicities are typically transient, chronic sequelae such as fibrosis, lymphedema, atrophy, telangiectasia, and dyspigmentation reflect uncontrolled tissue remodeling driven by sustained inflammation and fibroblast activation. Ionizing radiation generates reactive oxygen species that initiate vascular and epithelial injury, trigger immune infiltration, and perpetuate a cycle of transforming growth factor-β-driven myofibroblast differentiation, epithelial-to-mesenchymal transition, extracellular matrix deposition, and epigenetic reprogramming. Predicting and grading radiotherapy-induced skin fibrosis remains difficult: physician-reported scales lack sensitivity, and emerging imaging modalities and candidate tissue biomarkers require validation. Therapeutic strategies include pentoxifylline with vitamin E, oral statins, corticosteroids, fractional CO₂ and pulsed dye lasers, autologous fat grafting with adipose-derived stem cells, and manual therapies, each with varying efficacy. Investigational approaches such as deferoxamine, microneedling, and mesenchymal stem cell-based interventions show antifibrotic and regenerative potential, while candidate therapies including top

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansFibrosisSkinRadiodermatitisRadiotherapyDermatologyRadiation Injuries

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research